Navigation Links
Executive Changes at Ampio
Date:1/9/2012

GREENWOOD VILLAGE, Colo., Jan. 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced that CEO Don Wingerter would be granted a compassionate leave from all his duties at the company in order to attend to serious illnesses afflicting his closest family members.  The term of leave is currently unknowable and should be considered indefinite at this time.  Taking over the position of CEO will be Michael Macaluso, current Chairman of the Ampio Board of Directors and lead investor in DMI BioSciences, predecessor company to Ampio. 

Philip Coelho, Chairman of the Nominating and Governance committee of the Board, commented  "The entire Board would like to express our appreciation of all the excellent work performed by Don Wingerter over the last two years especially because we were all aware of the deteriorating health of his parents and saw the great strain that it was causing him.  We fully respect his decision to devote his full efforts to his family at this most urgent time and wish him all the best." 

"Fortunately for Ampio shareholders, Mr. Macaluso has agreed to assume the duties of CEO immediately and, in the unanimous opinion of the Board, could not be more qualified by intelligence, determination and knowledge of the issues before us.  Mr. Macaluso previously served as CEO managing the turn-around at Isolagen from August 2001 until September 2004. Isolagen's commercial efforts had been terminated by FDA intervention and the company was on the verge of bankruptcy.  Mr. Macaluso led a group of investors that provided Isolagen credit during the due diligence period and a significant investment thereafter.  As CEO, Mr. Macaluso quickly refocused the business goals of Isolagen, improved the relationship with the FDA, hired an accomplished management team, re-introduced the upgraded company to Institutional Investors and received FDA permission to proceed with a clinical trial of the company's lead product.  Having positioned the company for a successful future, Mr. Macaluso removed himself as CEO in September 2004 to make way for a more conventional CEO with pharmaceutical background leaving Isolagen with a market capitalization in excess of $300,000,000, more than $100,000,000 in cash and equivalents, an FDA sanctioned pivotal trial underway, a highly-institutionalized float and with three autologous cell laboratories constructed in England, Australia, and the United States ready for commercialization of the product.  Revenues had begun in the UK."

Dr. David Bar-Or, founder, Director and Chief Scientific Officer of Ampio, noted "For over three decades I was involved in research in underserved areas of medicine. I founded DMI BioSciences  and was able to perform substantial research and discovery in that company, but the business did not thrive. This all changed when I was introduced to Mr. Macaluso who became the lead investor and the driving force in transforming my discoveries into Ampio Pharmaceuticals Inc., a rapidly developing pharmaceutical business with active clinical trials of my lead drug discoveries.  To accomplish this transformation he has worked tirelessly over the last 30 months, without compensation, and made sure that all the DMI shareholders would benefit significantly from the future success of the company. In that respect, and in all his other actions, he has been remarkably fair and generous.  I am proud to be associated with this talented business person whose clear missions are to reward the shareholders and commercialize much needed remedies to many sufferers."

About Ampio
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.  For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact
Investor Relations, Ampio Pharmaceuticals, Inc.-- 720-437-6500

 


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. US HIFU Names New Chief Executive Officer
2. ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives
3. Novocure Adds Three Senior Oncology Executives to its Global Management Team
4. Veteran Healthcare and Pharmacy Executive Craig Stephens Joins Diplomat Specialty Pharmacy as Group Vice President of Business Development and Trade Relations
5. Essentialis Promotes Aaron Berg to Chief Executive Officer
6. Prasco Announces New, Expanded Roles for Key Executives
7. Tengion Appoints John L. Miclot President and Chief Executive Officer
8. Astellas Adds Two Key Senior Executives at Agensys, Inc.
9. Leading Executives Once Again Meet at GDS International’s Next Generation Pharmaceutical Manufacturing Europe Summit to Discuss Key Objectives For The Industry
10. Alacrita Launches Charity Auction of Executive One-to One Lunches with Senior Figures from the Pharmaceutical and Venture Capital Industries
11. Dune Medicals Chief Executive to Present at Upcoming Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), ... to their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis ... fast-evolving, high-growth hearing aid industry. The growing prevalence ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com today evaluates the ... SGYP ), Novo Nordisk A/S (NYSE: NVO ), ... Therapeutics Holdings Inc. (NASDAQ: PTX ). These stocks ... 19 th , 2017, finishing near its session lows. As ... over 0.7%, while shares of health care companies in the ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/21/2017)... Texas (PRWEB) , ... January 21, 2017 , ... ... performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
Breaking Medicine News(10 mins):